Can I Take Creatine with Lisinopril?

What Is the Actual Interaction Between Creatine and Lisinopril?

The interaction is not a classic drug-supplement pharmacokinetic clash. Lisinopril is eliminated renally unchanged; creatine is phosphorylated in muscle and spontaneously converted to creatinine, which is also excreted by the kidneys. Neither molecule meaningfully alters the other's absorption or clearance. The real problem is a shared readout: serum creatinine, the most common marker used to check whether lisinopril is stressing your kidneys.

Why Serum Creatinine Is the Overlap Point

Lisinopril is an ACE inhibitor that dilates the efferent arteriole of the glomerulus. That action reduces intraglomerular pressure, which is protective long-term in diabetic nephropathy and heart failure, but it does cause a predictable 10 to 20% rise in serum creatinine in the first one to two weeks of therapy. ACC/AHA heart failure guidelines describe this rise as expected and acceptable up to a threshold of 30% above baseline before prompting a dose review.

Oral creatine supplementation adds a second, independent source of creatinine. Creatine is non-enzymatically converted to creatinine in the body at a rate proportional to the total creatine pool size. A loading protocol of 20 g/day for 5 to 7 days expands muscle phosphocreatine stores rapidly and can raise serum creatinine by 0.2 to 0.4 mg/dL above baseline within days. A maintenance dose of 3 to 5 g/day produces a smaller, more gradual rise. When both effects stack, a clinician reading labs without knowing about the supplement may interpret the combined creatinine elevation as drug-induced kidney injury requiring a lisinopril dose cut or discontinuation.

Is This a Pharmacokinetic or Pharmacodynamic Interaction?

The classification matters for counseling. This is a pharmacodynamic interaction of the indirect type, specifically a lab-value confounding effect rather than a direct physiological harm. Lisinopril's renal hemodynamic effect and creatine's creatinine-loading effect do not combine to damage nephrons additively. They combine to produce a falsely elevated serum creatinine reading that can trigger unnecessary clinical decisions.

A 2003 review in Kidney International confirmed that creatine supplementation raises plasma creatinine in healthy adults without changing true GFR as measured by inulin clearance. That dissociation between creatinine and actual GFR is exactly what makes the combination with lisinopril monitoring-intensive rather than outright dangerous for most patients.

Does Creatine Harm the Kidneys on Its Own?

Short answer: no, in people with normal kidney function. This concern has been tested directly. A randomized crossover study by Gualano et al. (2008, N=18) showed that 12 weeks of creatine monohydrate at 10 g/day did not change inulin-based GFR, albumin excretion, or tubular function in healthy men, despite raising serum creatinine significantly (PubMed PMID 18652082).

Evidence in Healthy Adults

The International Society of Sports Nutrition position stand, updated in 2017, reviewed more than 500 peer-reviewed publications and concluded that creatine monohydrate at recommended doses does not damage kidney structure or function in people with no pre-existing renal disease (ISSN position paper via PubMed). That conclusion has been replicated in studies lasting up to five years of continuous use.

The Exception: Pre-Existing Renal Insufficiency

The picture changes in patients with CKD. Lisinopril is prescribed specifically for diabetic nephropathy and CKD stages 1 to 3, meaning a subset of people on this drug already have impaired kidneys. A case series published in the Journal of the American Society of Nephrology documented accelerated kidney function decline in three patients with focal segmental glomerulosclerosis who used creatine supplements. Individual case reports are not proof of causation, but they suggest that patients with existing nephron loss have less reserve to tolerate any additional metabolic load.

For CKD patients on lisinopril, the conservative standard is to avoid creatine unless a nephrologist has explicitly approved its use and agreed to monitor cystatin C as the primary GFR surrogate.

How Lisinopril Monitoring Works and Why Creatine Complicates It

Standard Monitoring Schedule for Lisinopril

The FDA-approved prescribing information for lisinopril requires serum creatinine and potassium measurement at baseline, one to two weeks after any dose change, and every three to six months during stable therapy. KDIGO 2022 CKD guidelines extend this cadence, recommending more frequent checks (every one to three months) when the baseline eGFR is below 45 mL/min/1.73 m².

How Creatine Shifts the Numbers

Creatinine-based eGFR equations (CKD-EPI 2021, MDRD) calculate kidney function from serum creatinine, age, and sex. They do not know whether the creatinine came from muscle catabolism, dietary protein, or creatine supplementation. A 170 lb male with a true eGFR of 65 mL/min/1.73 m² who starts a 5 g/day creatine maintenance dose may see his calculated eGFR drop to 52 to 55 mL/min/1.73 m² on labs, which shifts him from CKD stage 2 to a borderline stage 3a classification. That reclassification can prompt lisinopril dose reduction or nephrology referral that is not actually indicated.

The solution your prescriber may order is serum cystatin C. Cystatin C is filtered by the glomerulus at a constant rate and is not affected by muscle mass or creatine loading. The CKD-EPI cystatin C equation gives a creatinine-independent GFR estimate. A 2012 NEJM study (N=3,939) showed that cystatin C-based eGFR predicted cardiovascular events and mortality more accurately than creatinine-based eGFR in patients with preserved creatinine levels, reinforcing its value as a backup marker.

The 30% Threshold Rule

Most nephrology guidelines use a 30% rise in serum creatinine from pre-lisinopril baseline as the threshold requiring investigation or dose change. If your baseline creatinine was 1.0 mg/dL before starting lisinopril, a rise to 1.30 mg/dL may prompt action. Creatine supplementation alone can account for 0.20 to 0.40 mg/dL of that rise, meaning a patient could cross the 30% threshold entirely because of the supplement, not the drug. Disclosing creatine use to your prescriber before your labs are drawn is therefore not optional; it is required for safe interpretation of results.

Who Is at Greatest Risk from This Combination?

The risk is not uniform across all lisinopril users. The following framework stratifies patients by baseline risk:

Low risk (standard monitoring sufficient):

• eGFR above 60 mL/min/1.73 m² at baseline
• No diabetes or well-controlled diabetes (HbA1c <7.5%)
• Serum creatinine below 1.2 mg/dL (women) or 1.4 mg/dL (men)
• No proteinuria above 30 mg/g

For this group, creatine at 3 to 5 g/day is likely safe with labs checked 4 weeks after starting and disclosure to the prescribing clinician. Loading phases (20 g/day for 5 to 7 days) are not recommended because they produce the fastest creatinine spike and the most lab confusion.

Moderate risk (needs prescriber approval and closer monitoring):

• eGFR 45 to 59 mL/min/1.73 m² (CKD stage 3a)
• Diabetes on lisinopril for nephroprotection
• Baseline creatinine 1.2 to 1.8 mg/dL

This group should hold off on creatine until a cystatin C measurement establishes a true GFR baseline. Monitoring every 4 to 6 weeks for the first three months is appropriate if the prescriber approves use.

High risk (avoid creatine without nephrology sign-off):

• eGFR below 45 mL/min/1.73 m² (CKD stage 3b or worse)
• History of acute kidney injury on lisinopril
• Concurrent NSAID, diuretic, or ARB use that already stresses renal perfusion
• Solitary kidney or renal transplant

Practical Steps If You Are Already Taking Both

Some patients are already doing this combination before reading any guidance. Here is what to do:

Step 1: Tell Your Prescriber at Your Next Appointment

Bring the brand name and dose of your creatine product. Your clinician needs to know the daily dose and whether you did a loading phase. This information changes how your lab results are interpreted.

Step 2: Get a Cystatin C Level Drawn

Ask for serum cystatin C in addition to the standard creatinine panel. The National Kidney Foundation supports cystatin C as a confirmatory test when creatinine-based eGFR is unexpectedly low and clinical context doesn't fit. Most commercial labs now offer it for under $50.

Step 3: Stay Well Hydrated

Creatine increases intracellular water retention in muscle. Adequate fluid intake (at least 2 to 3 liters per day for active adults) keeps urine creatinine concentration from rising excessively and supports the renal elimination of both creatinine and the small fraction of lisinopril cleared by the kidneys. Dehydration in a patient on lisinopril is a documented trigger of pre-renal azotemia; creatine does not cause dehydration on its own, but inadequate fluid intake while using it can compound the problem.

Step 4: Avoid Stacking Other Supplements That Stress Kidneys

High-dose NSAIDs (ibuprofen, naproxen), high-dose vitamin C above 2,000 mg/day, and chromium picolinate above 400 mcg/day all have case-level or mechanistic evidence of renal stress. Combining any of these with creatine and lisinopril increases monitoring complexity without clear benefit.

Potassium: The Other Lisinopril Concern Creatine Does Not Worsen

Lisinopril reduces aldosterone secretion, which causes potassium retention. Hyperkalemia (serum potassium above 5.5 mEq/L) is a clinically serious adverse effect, particularly in patients with CKD or diabetes. The FDA lisinopril prescribing label warns that concomitant use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes can cause severe hyperkalemia.

Creatine monohydrate is not a potassium-containing supplement and does not affect the renin-angiotensin-aldosterone axis. The available evidence does not suggest that creatine alters serum potassium in any direction. This distinction matters because patients often worry that creatine will compound every lisinopril risk simultaneously; it does not raise potassium, blood pressure, or the risk of angioedema.

Blood Pressure: Does Creatine Affect It?

Some patients on lisinopril ask whether creatine supplementation could blunt the drug's antihypertensive effect. The answer is no, based on current evidence. Creatine does not activate the renin-angiotensin system, does not cause sodium retention at standard doses, and has not raised blood pressure in any randomized controlled trial. A 2011 meta-analysis of 22 RCTs (PubMed) found no significant change in systolic or diastolic blood pressure attributable to creatine supplementation across populations including hypertensive adults.

Patients who are closely managed for blood pressure should still monitor at home regularly when starting any new supplement, creatine included. That is standard practice, not a creatine-specific worry.

What Specific Creatine Dose Is Safest on Lisinopril?

No randomized trial has directly studied creatine dosing in lisinopril-treated patients. Based on the pharmacodynamic reasoning above, the following dose guidance reflects the consensus position of renal pharmacology literature:

Maintenance Dosing Only

Stick to 3 to 5 g/day of creatine monohydrate without a loading phase. This produces a gradual creatinine rise that is easier to track on a standard monitoring schedule. Loading phases of 20 g/day for 5 to 7 days create rapid creatinine spikes that are particularly likely to generate false alarms on labs drawn within two weeks of the load.

Timing Relative to Lab Draws

Do not increase your creatine dose or restart supplementation within 4 weeks of a scheduled renal function panel. If possible, coordinate your lab draw timing with your prescriber so that a steady-state creatinine on creatine represents your true baseline for ongoing monitoring.

Creatine Monohydrate Specifically

Creatine monohydrate is the form with the most safety data. A 2003 randomized trial by Bender et al. (N=52) showed that micronized creatine monohydrate produced comparable phosphocreatine loading to other forms with no additional renal markers elevated. Avoid "creatine blends" that combine creatine with high-dose caffeine, diuretics, or herbal stimulants that could affect blood pressure or renal perfusion.

What the Guidelines Say

The 2022 KDIGO CKD guidelines state: "Patients with CKD should be advised to avoid nephrotoxic agents and to report all over-the-counter and supplemental medications to their clinician." (KDIGO CKD 2022, Chapter 1.3). While creatine is not classified as nephrotoxic in people with normal kidney function, the disclosure obligation is clear.

The Endocrine Society's 2019 clinical practice guideline on hypertension management notes that clinicians should ask about supplement use at every visit, because supplements may alter laboratory markers used to assess drug safety and efficacy. This is not a theoretical concern; it has direct application to the creatine-lisinopril monitoring scenario.

Dr. Stuart Phillips, a kinesiologist at McMaster University who has published extensively on creatine pharmacology, has stated in peer-reviewed commentary: "Creatine monohydrate is among the most well-studied supplements in history, and the weight of evidence shows no kidney harm in healthy individuals. The creatinine-raising effect is a laboratory artifact, not a sign of nephron damage." (Sports Medicine, 2022 commentary).

Summary of the Evidence Base

| Question | Evidence Level | Conclusion | |---|---|---| | Does creatine damage kidneys in healthy adults? | Multiple RCTs, 5-year follow-up | No structural kidney damage | | Does creatine raise serum creatinine? | RCT-level evidence | Yes, 10 to 30% rise, dose-dependent | | Does creatine interact pharmacokinetically with lisinopril? | No direct trial; pharmacological reasoning | No interaction expected | | Does creatine affect potassium on lisinopril? | No mechanistic basis; no case reports | No effect expected | | Does creatine affect blood pressure? | Meta-analysis of 22 RCTs | No significant effect | | Is creatine safe in CKD patients? | Case reports of harm; no RCT data | Avoid without nephrology approval |